Latest News in the pharma Industry

Research & Development

Lilly's breast cancer study of abemaciclib demonstrated superior progression-free survival at interim analysis

Lilly's breast cancer study of abemaciclib demonstrated superior progression-free survival at interim analysis

24 Apr 2017

The Phase III study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer.

Read more 
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe

23 Apr 2017

Company receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers.

Read more 
BMS-986036 shows consistent improvement in liver fat, liver injury and fibrosis in patients with NASH in Phase II trial

BMS-986036 shows consistent improvement in liver fat, liver injury and fibrosis in patients with NASH in Phase II trial

23 Apr 2017

Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with BMS-986036.

Read more 
Allergan expands leading R&D NASH Program with Novartis Clinical Collaboration

Allergan expands leading R&D NASH Program with Novartis Clinical Collaboration

18 Apr 2017

Collaboration focused on Phase 2II clinical trial to evaluate use of Allergan's Cenicriviroc and Novartis' lead FXR agonist to treat NASH.

Read more 
FDA issues complete response letter for baricitinib

FDA issues complete response letter for baricitinib

16 Apr 2017

Additional clinical data are needed to determine the most appropriate doses.

Read more 
BMS to license anti-eTau and anti-myostatic compounds

BMS to license anti-eTau and anti-myostatic compounds

16 Apr 2017

Two separate agreements with Biogen and Roche.

Read more 
Regen BioPharma sees success in Its pre-clinical small molecule optimization program for NR2F6

Regen BioPharma sees success in Its pre-clinical small molecule optimization program for NR2F6

12 Apr 2017

The company's small molecule drug program is aimed at treating cancer and autoimmune diseases .

Read more 
BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumours

BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumours

12 Apr 2017

Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.

Read more 
Lhasa and Optibrium enter research and product development collaboration

Lhasa and Optibrium enter research and product development collaboration

11 Apr 2017

Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling.

Read more 
Phase III study shows Genentech’s Alecensa was superior to crizotinib in a specific type of lung cancer

Phase III study shows Genentech’s Alecensa was superior to crizotinib in a specific type of lung cancer

10 Apr 2017

Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment.

Read more 
New technology can detect tiny ovarian tumours

New technology can detect tiny ovarian tumours

10 Apr 2017

 “Synthetic biomarkers” could be used to diagnose ovarian cancer months earlier than now possible.

Read more 
Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD

Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD

9 Apr 2017

Botox is currently being studied as a potential treatment option for adult patients with moderate to severe MDD.

Read more